These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3133575)

  • 1. Systemic interferon therapy of multiple sclerosis: the pros.
    Knobler RL
    Neurology; 1988 Jul; 38(7 Suppl 2):58-61. PubMed ID: 3133575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function.
    Durelli L; Bongioanni MR; Cavallo R; Ferrero B; Ferri R; Verdun E; Bradac GB; Riva A; Geuna M; Bergamini L
    Mult Scler; 1995; 1 Suppl 1():S32-7. PubMed ID: 9345396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multiple sclerosis with various interferons: the cons.
    Johnson KP
    Neurology; 1988 Jul; 38(7 Suppl 2):62-5. PubMed ID: 3133576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early treatment trials with interferon beta in multiple sclerosis.
    Panitch HS
    Mult Scler; 1995; 1 Suppl 1():S17-21. PubMed ID: 9345392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
    Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK
    Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
    Kuzmits R; Scheithauer W; Ludwig H; Flener R
    Acta Med Austriaca; 1985; 12(5):129-34. PubMed ID: 3938590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients.
    Revel M; Chebath J; Mangelus M; Harroch S; Moviglia GA
    Mult Scler; 1995; 1 Suppl 1():S5-11. PubMed ID: 9345390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis.
    Noronha A; Toscas A; Jensen MA
    Ann Neurol; 1992 Jan; 31(1):103-6. PubMed ID: 1371908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of multiple sclerosis with interferons].
    Nogales-Gaete J; Arriagada C
    Rev Med Chil; 1996 May; 124(5):597-604. PubMed ID: 9035514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study.
    Comi G; Barkhof F; Durelli L; Edan G; Fernandez O; Filippi M; Hartung HP; Hommes OR; Seeldrayers P; Soelberg-Sorensen P
    Mult Scler; 1995; 1 Suppl 1():S24-7. PubMed ID: 9345394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antiviral treatment of chronic active hepatitis B. Combination therapy with beta interferon and recombinant gamma interferon].
    Eisenburg J; Caselmann W; Eder M; Pape GR
    Fortschr Med; 1988 Jul; 106(21):431-7. PubMed ID: 3146536
    [No Abstract]   [Full Text] [Related]  

  • 16. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.
    Camenga DL; Johnson KP; Alter M; Engelhardt CD; Fishman PS; Greenstein JI; Haley AS; Hirsch RL; Kleiner JE; Kofie VY
    Arch Neurol; 1986 Dec; 43(12):1239-46. PubMed ID: 3535752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic alpha-interferon therapy of multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CK; Kamin-Lewis RM; Johnson KP
    Neurology; 1984 Oct; 34(10):1273-9. PubMed ID: 6384817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical application of human fibroblast interferon (IFN) in cutaneous leishmaniasis.
    Trau H; Schewach-Millet M; Shoham J; Doerner T; Shor R; Passwell JH
    Isr J Med Sci; 1987 Nov; 23(11):1125-7. PubMed ID: 3325468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy.
    Becher B; Giacomini PS; Pelletier D; McCrea E; Prat A; Antel JP
    Ann Neurol; 1999 Feb; 45(2):247-50. PubMed ID: 9989628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.